Biovica International AB Class B (DE:9II)
FRANKFURT:9II
9II Stock Chart & Stats
€0.02
-€0.05(-28.13%)
At close: 4:00 PM EST
€0.02
-€0.05(-28.13%)
Day’s Range― - ―
52-Week Range€0.01 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.73M
Enterprise Value-€15.61M
Total Cash (Recent Filing)€88.22M
Total Debt (Recent Filing)€4.84M
Price to Earnings (P/E)―
Beta-1.09
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding277,487,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.50
Price to Sales (P/S)7.52
P/FCF Ratio-0.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€1.27M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityLow debt-to-equity (~0.05) gives Biovica financial flexibility typical for a biotech: it reduces short-term solvency risk, supports continued investment in commercialization and clinical validation, and lengthens runway versus highly leveraged peers while they scale revenues.
Consistent Revenue GrowthRevenue growth (TTM +~10%) reflects improving commercial traction for the DiviTum assays from a small base. Sustained top-line growth signals increasing adoption by labs, clinics and pharma partners, creating a path to scale fixed costs and potentially improve margins over time.
Diversified Revenue Model: Tests + Pharma CollaborationsA business model combining recurring diagnostic test sales with higher‑value pharma and research collaborations diversifies revenue streams. Clinical trial partnerships can fund assay use, validate clinical utility, and create durable commercial channels beyond single-market lab sales.
Bears Say
Large Cash BurnMaterial negative operating and free cash flow (~-65m TTM) shows the company cannot self-fund growth. Persistent cash burn forces reliance on external financing, raising dilution risk and constraining investment in sales, regulatory work, or R&D until operations become cash generative.
Negative Gross Profit And Heavy Operating LossesNegative gross profit indicates current unit economics do not cover direct costs and large operating losses mean core activities destroy value. Without structural margin improvement—lower cost of goods or higher pricing—scaling revenue may not lead to sustainable profitability.
Very Weak Returns On EquityROE near -96% signals shareholder capital is not generating returns and is being consumed by losses. Prolonged negative ROE undermines investor confidence, limits access to favorable capital, and increases the likelihood of equity dilution or strategic alternatives if profitability isn’t restored.
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €9.73M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Jun 17, 2026 which is in 68 days.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Mar 18, 2026. The company reported -€0.006 earnings per share for the quarter, beating the consensus estimate of -€0.007 by €0.002.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 277,487,200 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.006 in its last earnings report, beating expectations of -€0.007. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biovica International AB Class B
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
NextCell Pharma AB
―